Edition:
United States

Karolinska Development AB (KDEV.ST)

KDEV.ST on Stockholm Stock Exchange

5.35SEK
28 Apr 2017
Change (% chg)

-0.15kr (-2.73%)
Prev Close
5.50kr
Open
5.50kr
Day's High
5.50kr
Day's Low
5.35kr
Volume
8,127
Avg. Vol
24,344
52-wk High
9.75kr
52-wk Low
5.00kr

KDEV.ST

Chart for KDEV.ST

About

Karolinska Development AB is a Sweden-based investment company. The Company provides capital to biotechnology firms, as well as develops and commercializes biotechnological products. Its activities are involved in a range of areas: oncology, infections and wound healing, women’s health, cardiovascular and hematology, medical... (more)

Overall

Beta: 0.76
Market Cap(Mil.): kr345.58
Shares Outstanding(Mil.): 62.83
Dividend: --
Yield (%): --

Financials

  KDEV.ST Industry Sector
P/E (TTM): -- 34.67 30.12
EPS (TTM): -4.08 -- --
ROI: -42.04 12.55 13.28
ROE: -156.16 14.56 14.44

BRIEF-Karolinska Development announces outcome of set-off issue

* REG-KAROLINSKA DEVELOPMENT ANNOUNCES OUTCOME OF SET-OFF ISSUE

Apr 05 2017

BRIEF-Karolinska Development: research collaboration with Memorial Sloan Kettering Cancer Center

* Karolinska Development company Aprea Therapeutics announces research collaboration with Memorial Sloan Kettering Cancer Center

Mar 22 2017

BRIEF-Karolinska Development: Modus Therapeutics raises SEK 32 mln

* Karolinska Development company Modus Therapeutics raises 32 million Swedish crowns ($3.5 million)to support development of sevuparin for sickle cell disease

Feb 20 2017

BRIEF-Karolinska Development divests its holding in Inhalation Sciences

* Karolinska development divests its holding in Inhalation sciences Source text for Eikon: Further company coverage: (Reporting by Stockholm Newsroom)

Feb 13 2017

BRIEF-Karolinska Development offers set-off share issue to convertible holders

* Said on Monday will present a proposal to shareholders to approve its decision on a new issue of B-shares to the convertible holders offering the convertible holders to "set-off" their convertibles as payment for new B-shares

Feb 07 2017

BRIEF-Karolinska Development: OssDsign signs distribution agreement in USA

* Says its portfolio company OssDsign announces agreement for distribution of OSSDSIGN Cranial in the USA with Matador Medical Inc. Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Feb 02 2017

BRIEF-Karolinska Development: OssDsign gets FDA clearance for marketing of OSSDSIGN Cranial in USA

* Its portfolio company OssDsign announces FDA 510(k) clearance for marketing of OSSDSIGN Cranial for sale in USA

Jan 20 2017

BRIEF-Karolinska Development: OssDsign announces new European partnerships

* Its portfolio company OssDsign AB announces new European partnerships for commercialization of novel medical implants

Jan 12 2017

BRIEF-Karolinska Development Q3 operating loss narrows to SEK 7.0 million

* Q3 net sales 0.4 million Swedish crowns ($43,451) versus 0.3 million crowns year ago

Nov 23 2016

BRIEF-Karolinska Development's Umecrine Cognition raises SEK 45 mln to advance GR3027

* Umecrine Cognition raises 45 million Swedish crowns ($4.9 million) to advance GR3027, a novel drug candidate for hepatic encephalopathy

Nov 22 2016

More From Around the Web

Earnings vs. Estimates